Mizue Hasegawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mizue Hasegawa has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Fumikazu Sakai
Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Japan
6 shared publicationsHideki Katsura
Department of Pulmonary Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan
5 shared publicationsEitetsu Koh
Division of Thoracic Surgery, Tokyo Women's Medical University Yachiyo Medical Center, Japan
4 shared publicationsKenzo Hiroshima
Division of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Japan
4 shared publicationsYasuo Sekine
Division of Thoracic Surgery, Tokyo Women's Medical University Yachiyo Medical Center, Japan
4 shared publicationsAkitoshi Sato
The First Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo 162-8666, Japan
3 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8703
Impact of Bronchiectasis on Long-Term Mortality in Patients with Rheumatoid Arthritis: A Real-World Retrospective Cohort Study
Objectives: This study aimed to examine the impact of bronchiectasis on long-term mortality in patients with rheumatoid arthritis (RA). Methods: We used real-world cohort data from patients who were diagnosed with RA at our institution between April 2001 and June 2023. Pulmonary conditions were evaluated using high-resolution computed tomography imaging taken at RA diagnosis and over the disease course. Traction bronchiectasis was not included in the diagnosis of bronchiectasis. Results: Among 766 patients with RA, 2.7% were diagnosed with bronchiectasis plus interstitial lung disease (ILD), 5.6% with bronchiectasis alone, and 7.3% with ILD alone. During follow-up with a mean of 9.7 years, the crude incidence rate of death (95% confidence interval [CI]) per 100 person-years was 11.1 (6.7–18.4) in RA patients with bronchiectasis plus ILD; 7.0 (4.6–10.5) in those with bronchiectasis alone; 6.8 (4.6–10.1) in those with ILD alone; and 1.2 (1.0–1.5) in those without either complication. The standardized mortality ratio (95% CI) compared with the general population was 2.57 (1.76–3.39) for RA patients with bronchiectasis; 2.17 (1.50–2.85) for those with ILD; and 0.93 (0.73–1.14) for those without either complication. In multivariable Cox regression analysis using RA diagnosis as the index date and treating pulmonary complications as time-varying exposure variables, the presence of bronchiectasis alone or ILD alone, advanced age, and low body mass index were identified as strong predictive factors for death. The adjusted hazard ratio (95% CI) was 2.37 (1.48–3.82) for bronchiectasis alone and 3.16 (1.92–5.22) for ILD alone. When limited to bronchiectasis patients with and without ILD, the complication of ILD did not influence the mortality risk. Conclusions: Bronchiectasis was associated with excess mortality in RA patients, regardless of the complication of ILD. Bronchiectasis and ILD had similar levels of increased mortality risk in RA patients.
- 7 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8703
Open AccessImpact of Bronchiectasis on Long-Term Mortality in Patients with Rheumatoid Arthritis: A Real-World Retrospective Cohort Study
Objectives: This study aimed to examine the impact of bronchiectasis on long-term mortality in patients with rheumatoid arthritis (RA). Methods: We used real-world cohort data from patients who were diagnosed with RA at our institution between April 2001 and June 2023. Pulmonary conditions were evaluated using high-resolution computed tomography imaging taken at RA diagnosis and over the disease course. Traction bronchiectasis was not included in the diagnosis of bronchiectasis. Results: Among 766 patients with RA, 2.7% were diagnosed with bronchiectasis plus interstitial lung disease (ILD), 5.6% with bronchiectasis alone, and 7.3% with ILD alone. During follow-up with a mean of 9.7 years, the crude incidence rate of death (95% confidence interval [CI]) per 100 person-years was 11.1 (6.7–18.4) in RA patients with bronchiectasis plus ILD; 7.0 (4.6–10.5) in those with bronchiectasis alone; 6.8 (4.6–10.1) in those with ILD alone; and 1.2 (1.0–1.5) in those without either complication. The standardized mortality ratio (95% CI) compared with the general population was 2.57 (1.76–3.39) for RA patients with bronchiectasis; 2.17 (1.50–2.85) for those with ILD; and 0.93 (0.73–1.14) for those without either complication. In multivariable Cox regression analysis using RA diagnosis as the index date and treating pulmonary complications as time-varying exposure variables, the presence of bronchiectasis alone or ILD alone, advanced age, and low body mass index were identified as strong predictive factors for death. The adjusted hazard ratio (95% CI) was 2.37 (1.48–3.82) for bronchiectasis alone and 3.16 (1.92–5.22) for ILD alone. When limited to bronchiectasis patients with and without ILD, the complication of ILD did not influence the mortality risk. Conclusions: Bronchiectasis was associated with excess mortality in RA patients, regardless of the complication of ILD. Bronchiectasis and ILD had similar levels of increased mortality risk in RA patients.
- Open Access
- 19 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1380
Mortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study
Objective: The aim of this study was to determine mortality and predictive factors for death in patients with rheumatoid arthritis (RA) diagnosed with and without interstitial lung disease (ILD). Methods: We retrospectively performed a long-term follow-up study of patients diagnosed with RA at our medical center between April 2001 and June 2023. The diagnosis and classification of ILD were made based on pulmonary high-resolution computed tomography (HRCT), taken at RA diagnosis and during follow-up. Results: Among 781 patients with RA, 78 were diagnosed with ILD; all cases except one were subclinical. The most common HRCT pattern was definite usual interstitial pneumonia (UIP) followed by nonspecific interstitial pneumonia (NSIP)/UIP, probable UIP, NSIP, and early UIP. During follow-up (mean of 10.0 years), the crude incidence rate of death (95% confidence interval [CI]) was 7.1 (5.2–10.0) and 1.5 (1.0–1.9) per 100 person-years in RA patients with and without ILD. Poor control of RA activity was associated with increased incidence rates of death. The standardized mortality ratio (95% CI) compared with the general population was 1.32 (1.11–1.53) for all RA patients, 2.09 (1.45–2.73) for RA-ILD patients, and 1.16 (0.95–1.38) for non-ILD RA patients. Lung cancer and respiratory failure were the most common causes of death in RA-ILD patients. The Multivariable Fine-Gray regression analysis revealed that ILD (adjusted hazard ratio [HR] 2.97 [95% CI 1.95–4.53]), advanced age (1.08 per additional year [1.05–1.10]), and low body mass index (3.07 [2.10–4.49]) were strong predictive factors for mortality in RA patients. HRCT patterns did not affect the risk of death in RA-ILD patients. Conclusions: Regardless of HRCT pattern, RA-ILD contributes to the increased mortality risk in patients with RA.
- 19 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1380
Open AccessMortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study
Objective: The aim of this study was to determine mortality and predictive factors for death in patients with rheumatoid arthritis (RA) diagnosed with and without interstitial lung disease (ILD). Methods: We retrospectively performed a long-term follow-up study of patients diagnosed with RA at our medical center between April 2001 and June 2023. The diagnosis and classification of ILD were made based on pulmonary high-resolution computed tomography (HRCT), taken at RA diagnosis and during follow-up. Results: Among 781 patients with RA, 78 were diagnosed with ILD; all cases except one were subclinical. The most common HRCT pattern was definite usual interstitial pneumonia (UIP) followed by nonspecific interstitial pneumonia (NSIP)/UIP, probable UIP, NSIP, and early UIP. During follow-up (mean of 10.0 years), the crude incidence rate of death (95% confidence interval [CI]) was 7.1 (5.2–10.0) and 1.5 (1.0–1.9) per 100 person-years in RA patients with and without ILD. Poor control of RA activity was associated with increased incidence rates of death. The standardized mortality ratio (95% CI) compared with the general population was 1.32 (1.11–1.53) for all RA patients, 2.09 (1.45–2.73) for RA-ILD patients, and 1.16 (0.95–1.38) for non-ILD RA patients. Lung cancer and respiratory failure were the most common causes of death in RA-ILD patients. The Multivariable Fine-Gray regression analysis revealed that ILD (adjusted hazard ratio [HR] 2.97 [95% CI 1.95–4.53]), advanced age (1.08 per additional year [1.05–1.10]), and low body mass index (3.07 [2.10–4.49]) were strong predictive factors for mortality in RA patients. HRCT patterns did not affect the risk of death in RA-ILD patients. Conclusions: Regardless of HRCT pattern, RA-ILD contributes to the increased mortality risk in patients with RA.
- 12 February 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (6) , 1017-1022
CT assessment of axillary lymphadenopathy in patients with rheumatoid arthritis: association with disease activity and severity
Axillary lymph nodes (ALNs) are often seen on chest computed tomography (CT) in rheumatoid arthritis (RA) patients. Early reports described lymphadenopathy as one of the systemic manifestations rather than regional lymphadenopathy secondary to drainage from the affected joints. Subsequently, the importance of the immunological events occurring in draining lymph nodes in the development of arthritis was documented.
- 12 February 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (6) , 1017-1022
CT assessment of axillary lymphadenopathy in patients with rheumatoid arthritis: association with disease activity and severity
Axillary lymph nodes (ALNs) are often seen on chest computed tomography (CT) in rheumatoid arthritis (RA) patients. Early reports described lymphadenopathy as one of the systemic manifestations rather than regional lymphadenopathy secondary to drainage from the affected joints. Subsequently, the importance of the immunological events occurring in draining lymph nodes in the development of arthritis was documented.
- 1 November 2017
- Published by Elsevier in Respiratory Investigation
- Vol. 55 (6) , 365-371
The efficacy of transbronchial needle aspiration with endobronchial ultrasonography using a guide sheath for peripheral pulmonary lesions suspected to be lung cancer
- 1 November 2017
- Published by Elsevier in Respiratory Investigation
- Vol. 55 (6) , 365-371
The efficacy of transbronchial needle aspiration with endobronchial ultrasonography using a guide sheath for peripheral pulmonary lesions suspected to be lung cancer
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (8) , 937-941
Rosai-Dorfman Disease of the Lung Overlapping with IgG4-related Disease: The Difficulty in Its Differential Diagnosis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (8) , 937-941
Open AccessRosai-Dorfman Disease of the Lung Overlapping with IgG4-related Disease: The Difficulty in Its Differential Diagnosis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (21) , 2899-2902
Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (21) , 2899-2902
Open AccessIntravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2016
- Published by Japan Lung Cancer Society in Haigan
- Vol. 56 (2) , 114-118
A Case of Pulmonary Carcinoma with Pulmonary Tuberculosis Diagnosed During Surgery After Induction Chemotherapy
背景.肺癌と肺結核については合併頻度が高いことが示されており,その可能性については常に考慮する必要がある.症例.75歳,男性.左上葉肺腺癌(cT2aN3M0 IIIB)の診断で,導入化学療法(CDDP+PEM 2コース)を施行した.治療効果はPRであり原発巣以外のリンパ節病変はほぼ消失を認め,胸腔鏡下左上葉切除およびリンパ節郭清術を施行した.下葉にも腫瘤を触知し,下葉の部分切除も行った.手術の結果,肺癌はpT2aN1M0 IIAであり,部分切除した腫瘤は結核腫と診断された.術後喀痰でも肺結核と診断され,抗結核薬による治療を行った.化学療法開始前には下葉に腫瘤影を認めず,結核と診断された病変は化学療法後に発症した可能性が示唆された.結論.肺癌と肺結核の合併は頻度が高く,また一方の治療経過中に続発,増悪する可能性もあり得る.合併の際には早急な診断,治療が必要であり,常に念頭に置き診療に当たる必要があると考えられた.
- 1 January 2016
- Published by Japan Lung Cancer Society in Haigan
- Vol. 56 (2) , 114-118
A Case of Pulmonary Carcinoma with Pulmonary Tuberculosis Diagnosed During Surgery After Induction Chemotherapy
背景.肺癌と肺結核については合併頻度が高いことが示されており,その可能性については常に考慮する必要がある.症例.75歳,男性.左上葉肺腺癌(cT2aN3M0 IIIB)の診断で,導入化学療法(CDDP+PEM 2コース)を施行した.治療効果はPRであり原発巣以外のリンパ節病変はほぼ消失を認め,胸腔鏡下左上葉切除およびリンパ節郭清術を施行した.下葉にも腫瘤を触知し,下葉の部分切除も行った.手術の結果,肺癌はpT2aN1M0 IIAであり,部分切除した腫瘤は結核腫と診断された.術後喀痰でも肺結核と診断され,抗結核薬による治療を行った.化学療法開始前には下葉に腫瘤影を認めず,結核と診断された病変は化学療法後に発症した可能性が示唆された.結論.肺癌と肺結核の合併は頻度が高く,また一方の治療経過中に続発,増悪する可能性もあり得る.合併の際には早急な診断,治療が必要であり,常に念頭に置き診療に当たる必要があると考えられた.
- Open Access
- 1 October 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (12) , 1239-1242
FISH Analysis of Intrapulmonary Malignant Mesothelioma without a Clinically Detectable Primary Pleural Lesion: An Autopsy Case
Patients with malignant mesothelioma typically present with a pleural effusion or pleural thickening and masses. A rare autopsy case of mesothelioma presenting with multiple bilateral lung nodules without clinically detectable pleural lesions is presented. A definitive diagnosis of the video-assisted thoracic surgery specimen could not be made, though a pattern of fibrosis mimicking organizing pneumonia was identified. Despite corticosteroid therapy, follow-up chest computed tomography showed enlargement of multiple nodules accompanied by the appearance of pleural thickening and effusions. The patient died of respiratory failure 11 months after initial presentation. Autopsy and retrospective analysis of the video-assisted thoracic surgery specimen using a p16 fluorescence in situ hybridization assay showed p16 homozygous deletion. The final diagnosis was sarcomatoid mesothelioma, and the lung nodules were intrapulmonary metastases from a clinically undetectable pleural sarcomatoid mesothelioma. It is important both to consider the possibility of mesothelioma with unusual clinical, radiological and pathological presentations and to remember that p16 fluorescence in situ hybridization analysis can play an important role in the diagnosis of mesothelioma.
- 1 October 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (12) , 1239-1242
Open AccessFISH Analysis of Intrapulmonary Malignant Mesothelioma without a Clinically Detectable Primary Pleural Lesion: An Autopsy Case
Patients with malignant mesothelioma typically present with a pleural effusion or pleural thickening and masses. A rare autopsy case of mesothelioma presenting with multiple bilateral lung nodules without clinically detectable pleural lesions is presented. A definitive diagnosis of the video-assisted thoracic surgery specimen could not be made, though a pattern of fibrosis mimicking organizing pneumonia was identified. Despite corticosteroid therapy, follow-up chest computed tomography showed enlargement of multiple nodules accompanied by the appearance of pleural thickening and effusions. The patient died of respiratory failure 11 months after initial presentation. Autopsy and retrospective analysis of the video-assisted thoracic surgery specimen using a p16 fluorescence in situ hybridization assay showed p16 homozygous deletion. The final diagnosis was sarcomatoid mesothelioma, and the lung nodules were intrapulmonary metastases from a clinically undetectable pleural sarcomatoid mesothelioma. It is important both to consider the possibility of mesothelioma with unusual clinical, radiological and pathological presentations and to remember that p16 fluorescence in situ hybridization analysis can play an important role in the diagnosis of mesothelioma.
- Open Access
- 30 January 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (3) , 278-281
EGFR Mutation of Adenocarcinoma in Congenital Cystic Adenomatoid Malformation/Congenital Pulmonary Airway Malformation: A Case Report
An 80-year-old man underwent right upper lobectomy for the resection of multiple cysts accompanied by a nodule. The pathological diagnosis was adenocarcinoma with surrounding atypical epithelial cell proliferation in a Type 1 congenital cystic adenomatoid malformation/congenital pulmonary airway malformation. There was epidermal growth factor receptor mutation in the adenocarcinoma and surrounding atypical epithelial cells that had proliferated. Malignant transformation of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation may be related to the epidermal growth factor receptor pathway in this case, with atypical epithelial cell proliferation as a precursor. We emphasize the importance of complete resection of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation and the possibility of treatment with epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutated cases.
- 30 January 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (3) , 278-281
Open AccessEGFR Mutation of Adenocarcinoma in Congenital Cystic Adenomatoid Malformation/Congenital Pulmonary Airway Malformation: A Case Report
An 80-year-old man underwent right upper lobectomy for the resection of multiple cysts accompanied by a nodule. The pathological diagnosis was adenocarcinoma with surrounding atypical epithelial cell proliferation in a Type 1 congenital cystic adenomatoid malformation/congenital pulmonary airway malformation. There was epidermal growth factor receptor mutation in the adenocarcinoma and surrounding atypical epithelial cells that had proliferated. Malignant transformation of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation may be related to the epidermal growth factor receptor pathway in this case, with atypical epithelial cell proliferation as a precursor. We emphasize the importance of complete resection of congenital cystic adenomatoid malformation/congenital pulmonary airway malformation and the possibility of treatment with epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutated cases.
- 1 January 2011
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 100 (6) , 1545-1551
1. Approach to Diagnosis, 2) Radiological Findings of ALI/ARDS.
- 1 January 2011
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 100 (6) , 1545-1551
1. Approach to Diagnosis, 2) Radiological Findings of ALI/ARDS.